Two Sigma Advisers LP Decreases Holdings in Eli Lilly And Co (LLY)

Two Sigma Advisers LP lessened its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 38.1% during the 4th quarter, HoldingsChannel reports. The firm owned 529,000 shares of the company’s stock after selling 326,095 shares during the period. Two Sigma Advisers LP’s holdings in Eli Lilly And Co were worth $61,216,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the company. FDx Advisors Inc. increased its stake in shares of Eli Lilly And Co by 48.3% during the fourth quarter. FDx Advisors Inc. now owns 19,504 shares of the company’s stock worth $2,257,000 after buying an additional 6,356 shares during the period. State of Alaska Department of Revenue increased its stake in shares of Eli Lilly And Co by 3.3% during the fourth quarter. State of Alaska Department of Revenue now owns 204,487 shares of the company’s stock worth $23,660,000 after buying an additional 6,474 shares during the period. Waverton Investment Management Ltd increased its stake in shares of Eli Lilly And Co by 1.9% during the fourth quarter. Waverton Investment Management Ltd now owns 12,724 shares of the company’s stock worth $1,472,000 after buying an additional 238 shares during the period. Pennsylvania Trust Co increased its stake in shares of Eli Lilly And Co by 46.4% during the fourth quarter. Pennsylvania Trust Co now owns 85,021 shares of the company’s stock worth $9,839,000 after buying an additional 26,947 shares during the period. Finally, Sumitomo Life Insurance Co. increased its stake in shares of Eli Lilly And Co by 2.7% during the fourth quarter. Sumitomo Life Insurance Co. now owns 30,683 shares of the company’s stock worth $3,551,000 after buying an additional 800 shares during the period. 79.59% of the stock is currently owned by institutional investors and hedge funds.

In other news, major shareholder Lilly Endowment Inc sold 51,766 shares of the company’s stock in a transaction on Tuesday, January 15th. The stock was sold at an average price of $117.74, for a total transaction of $6,094,928.84. Following the completion of the sale, the insider now directly owns 117,963,538 shares of the company’s stock, valued at $13,889,026,964.12. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Alfonso G. Zulueta sold 4,000 shares of the company’s stock in a transaction on Thursday, January 31st. The shares were sold at an average price of $120.00, for a total value of $480,000.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 834,190 shares of company stock valued at $102,516,602. 0.11% of the stock is currently owned by company insiders.



A number of analysts recently weighed in on LLY shares. Citigroup lowered shares of Eli Lilly And Co from a “buy” rating to a “neutral” rating and set a $115.00 target price on the stock. in a research note on Monday, November 26th. Zacks Investment Research raised Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $128.00 price target for the company in a research note on Wednesday, November 28th. BMO Capital Markets restated a “buy” rating on shares of Eli Lilly And Co in a report on Wednesday, December 19th. Morgan Stanley set a $116.00 price objective on Eli Lilly And Co and gave the company a “hold” rating in a report on Thursday, December 20th. Finally, Argus restated a “buy” rating on shares of Eli Lilly And Co in a report on Thursday, December 27th. Ten investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $115.68.

Shares of Eli Lilly And Co stock opened at $128.30 on Monday. The company has a quick ratio of 1.38, a current ratio of 1.73 and a debt-to-equity ratio of 1.07. The firm has a market capitalization of $132.84 billion, a PE ratio of 23.12, a PEG ratio of 2.57 and a beta of 0.33. Eli Lilly And Co has a fifty-two week low of $74.51 and a fifty-two week high of $130.75.

Eli Lilly And Co (NYSE:LLY) last announced its earnings results on Wednesday, February 6th. The company reported $1.33 EPS for the quarter, missing the consensus estimate of $1.36 by ($0.03). Eli Lilly And Co had a net margin of 13.16% and a return on equity of 44.66%. The company had revenue of $6.44 billion for the quarter, compared to analysts’ expectations of $6.28 billion. During the same period in the prior year, the company earned $1.14 earnings per share. The company’s revenue for the quarter was up 4.5% on a year-over-year basis. Equities analysts anticipate that Eli Lilly And Co will post 5.66 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Two Sigma Advisers LP Decreases Holdings in Eli Lilly And Co (LLY)” was originally published by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://dakotafinancialnews.com/2019/03/25/two-sigma-advisers-lp-decreases-holdings-in-eli-lilly-and-co-lly.html.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: The Structure of a Futures Contract

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly And Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.